

Malaysia Results Review

26 November 2025

Agriculture | Agriculture

Leong Hup International (LHIB MK)

Buy (Maintained)

Lifted By Strong Indonesia Recovery; Stay BUY

Target Price (Return): MYR0.98 (+58%)
Price (Market Cap): MYR0.62 (USD521m)
ESG score: 2.6 (out of 4)
Avg Daily Turnover (MYR/USD) 2.11m/0.51m

• Maintain BUY and TP of MYR0.98, 58% upside and c.5% FY26F yield. Leong Hup International's 9M25 results beat expectations thanks to its stronger-than-expected profit margin. Notwithstanding the forecasted negative earnings growth ahead, we believe the fundamental improvement in the poultry industry driven by cost tailwinds and market consolidation has yet to be priced in. Trading at -1.5 SD from its 5-year mean, valuation is attractive for a player with an established regional presence to capture the resilient poultry consumption.

Analyst

Soong Wei Siang +603 2302 8130 soong.wei.siang@rhbgroup.com




• LHIB's 9M25 results were above expectations. Core net profit of MYR310m (+11%) accounted for 82% and 80% of our and consensus forecasts. This is as profit margins held up steadily supported by favourable market conditions and feed costs. Post results, we raise FY25F-27F earnings by 14%, 12%, and 10%. However, we keep our DCF-derived TP unchanged at MYR0.98, which implies an 8% ESG discount and 9x FY26F P/E to be largely in line with regional peers.

Share Performance (%)

	YTD	1m	3m	6m	12m		
Absolute	2.5	(6.8)	(4.6)	(4.6)	(2.4)		
Relative	4.1	(6.8)	(5.5)	(9.9)	(3.6)		
52-wk Price lo	w/high (M	1YR)		0.57 -0.67			

• Results review. YoY, 9M25 revenue fell 6% to MYR6.6bn, a function of lower ASPs in tandem with the fall in feed costs. In addition, overseas operations also saw the translation of lower revenue as a result of the strengthened MYR. Meanwhile, 9M25 EBITDA fell marginally by 3% as the sharp drop in Indonesia (46%) was mitigated by the solid performance in other key operating markets. That said, core net profit grew 11% to MYR310m thanks to lower interest expenses (-26%) and lower minority interests dilution due to the lower Indonesia earnings. QoQ, 3Q25 revenue grew 4% with most operating markets recording healthy growth. 3Q25 core net profit surged 30% QoQ thanks to the recovery in the Indonesian market underpinned by improved market conditions.



• Outlook. Looking ahead in 4Q25, Malaysia market could see softer earnings as the full impact of egg subsidy termination will be reflected. Meanwhile, the strong Indonesia earnings contribution could sustain on elevated ASPs. Beyond the immediate term, we believe the overall fundamentals of the poultry industry have improved with the pandemic and commodity supercycle phasing out the smaller and weaker players. This has led to industry consolidation which is favourable to large industry players like LHIB. Coupled with a sturdier balance sheet (net gearing has shrunk to 0.39x in 3Q25 from 1.1x in FY22), we believe the group is well-positioned to capture more market share and improve on its efficiency level via capacity expansion.

Source: Bloomberg

•	RISKS to our	recommendation	include a	snarp	rise	ın	input	COSTS	and
	unfavourable	demand-supply ind	ustry dyna	mics.					

Forecasts and Valuation	Dec-23	Dec-24	Dec-25F	Dec-26F	Dec-27F
Total turnover (MYRm)	9,540	9,309	8,793	9,056	9,490
Recurring net profit (MYRm)	324	446	430	401	414
Recurring net profit growth (%)	59.3	37.6	(3.7)	(6.6)	3.0
Recurring P/E (x)	6.98	5.07	5.27	5.64	5.47
P/B (x)	1.0	0.9	0.8	0.7	0.7
P/CF (x)	2.61	2.29	3.00	3.34	3.34
Dividend Yield (%)	4.8	4.4	5.7	5.3	5.5
EV/EBITDA (x)	4.50	3.60	3.36	3.20	2.90
Return on average equity (%)	14.2	18.3	16.5	13.9	13.0
Net debt to equity (%)	59.5	36.8	25.8	18.3	11.6

Overall ESG Score: 2.6 (out of 4)

E Score: 2.4 (GOOD) S Score: 2.7 (GOOD) G Score: 3.0 (GOOD)

Please refer to the ESG analysis on the next page

Source: Company data, RHB

Emissions And ESG

Trend analysis

Started tracking emissions in FY24.

			Dec-25
-	-	220,472	-
-	-	298,518	-
-	-	-	-
na	na	518,990	na
	-		298,518

Source: Company data, RHB

Latest ESG-Related Developments

The transition to rice husks, wood chips and palm kernel shells as renewable biomass energy sources to replace coal-powered boilers contributed to a material reduction of GHG emissions.

Solar energy installation experienced an increase of 65%, rising from $9,570,070\,\mathrm{kWh}$ to $15,752,775\,\mathrm{kWh}$ in FY24.

Contributed more than MYR1m worth of monetary donations, food supplies, detergents, and essential consumer products to frontline hospital healthcare staff, firefighters, police officers and those in need.

Only 25% of LHIB's procurement expenses were allocated to foreign suppliers for raw materials in FY24, underscoring the commitment to support the local economy.

ESG Unbundled

Overall ESG Score: 2.6 (out of 4)

Last Updated: 30 May 2025

E Score: 2.4 (GOOD)

The transition to rice husks, wood chips and palm kernel shells as renewable biomass energy sources to replace coal-powered boilers contributed to a material reduction of GHG emissions. Solar energy installation experienced an increase of 65%, rising from 9,570,070 kWh to 15,752,775 kWh in FY24. Contributed more than MYR1.4m worth of monetary donations, food supplies, detergents, and essential consumer products to frontline hospital healthcare staff. firefighters, police officers and those in need. Only 25% of LHIB's procurement expenses were allocated to foreign suppliers for raw materials in FY24, underscoring the commitment to support the local economy.


S Score: 2.7 (GOOD)

Good policy to enhance the awareness of health and safety amongst its stakeholders and putting in place a framework that ensure a safe and conducive working environment for its people. In addition, LHIB also practices good standard in ensuring the safety and quality of food products.

G Score: 3.0 (GOOD)

LHIB has applied and adopted the majority of the best practices of the Malaysian Code on Corporate Governance with independent directors comprising of almost 50% of the board with women making up 30% of it.

ESG Rating History



Source: RHB



Financial Exhibits

Asia Malaysia Agriculture Leong Hup International LHIB MK Buy

Valuation basis

Discounted Cash Flow

Key drivers

- i. Regional expansion plan;
- ii. Favourable product prices.

- i. Unfavourable change in regulatory policy;ii. Unfavourable demand-supply dynamics.

Company Profile

Leong Hup International is on one of the largest fullyintegrated producers of poultry, eggs, and livestock feeds in South-East Asia.

Financial summary (MYR)	Dec-23	Dec-24	Dec-25F	Dec-26F	Dec-27F
Recurring EPS	0.09	0.12	0.12	0.11	0.11
DPS	0.03	0.03	0.04	0.03	0.03
BVPS	0.61	0.67	0.75	0.83	0.91
Return on average equity (%)	14.2	18.3	16.5	13.9	13.0

Valuation metrics	Dec-23	Dec-24	Dec-25F	Dec-26F	Dec-27F
Recurring P/E (x)	6.98	5.07	5.27	5.64	5.47
P/B (x)	1.0	0.9	0.8	0.7	0.7
FCF Yield (%)	28.6	29.4	17.9	14.4	7.9
Dividend Yield (%)	4.8	4.4	5.7	5.3	5.5
EV/EBITDA (x)	4.50	3.60	3.36	3.20	2.90
EV/EBIT (x)	6.49	4.87	4.76	4.67	4.29

Income statement (MYRm)	Dec-23	Dec-24	Dec-25F	Dec-26F	Dec-27F
Total turnover	9,540	9,309	8,793	9,056	9,490
Gross profit	1,484	1,549	1,608	1,639	1,716
EBITDA	1,043	1,204	1,204	1,196	1,240
Depreciation and amortisation	(319)	(313)	(353)	(377)	(400)
Operating profit	724	891	850	819	840
Net interest	(170)	(131)	(101)	(96)	(91)
Pre-tax profit	555	761	750	723	749
Taxation	(125)	(130)	(165)	(159)	(165)
Reported net profit	302	429	430	401	414
Recurring net profit	324	446	430	401	414

Cash flow (MYRm)	Dec-23	Dec-24	Dec-25F	Dec-26F	Dec-27F
Change in working capital	(32)	69	35	(39)	(62)
Cash flow from operations	868	989	754	677	678
Capex	(221)	(324)	(350)	(350)	(500)
Cash flow from investing activities	(140)	(345)	(350)	(350)	(500)
Dividends paid	(77)	(100)	(129)	(120)	(124)
Cash flow from financing activities	(773)	(720)	(325)	(317)	(315)
Cash at beginning of period	840	700	771	965	1,084
Net change in cash	(45)	(76)	79	10	(137)
Ending balance cash	795	623	850	975	947

Balance sheet (MYRm)	Dec-23	Dec-24	Dec-25F	Dec-26F	Dec-27F
Total cash and equivalents	700	771	965	1,084	1,212
Tangible fixed assets	2,730	2,683	2,730	2,753	2,753
Total investments	40	31	31	31	31
Total assets	6,527	6,444	6,654	6,845	7,050
Short-term debt	1,587	1,419	1,400	1,300	1,200
Total long-term debt	871	576	500	500	500
Total liabilities	3,571	3,117	3,025	2,936	2,851
Total equity	2,955	3,327	3,628	3,909	4,199
Total liabilities & equity	6,527	6,444	6,654	6,845	7,050

Key metrics	Dec-23	Dec-24	Dec-25F	Dec-26F	Dec-27F
Revenue growth (%)	5.5	(2.4)	(5.5)	3.0	4.8
Recurrent EPS growth (%)	59.3	37.6	(3.7)	(6.6)	3.0
Gross margin (%)	15.6	16.6	18.3	18.1	18.1
Operating EBITDA margin (%)	10.9	12.9	13.7	13.2	13.1
Net profit margin (%)	3.2	4.6	4.9	4.4	4.4
Dividend payout ratio (%)	36.3	23.4	30.0	30.0	30.0
Capex/sales (%)	2.3	3.5	4.0	3.9	5.3
Interest cover (x)	4.27	6.82	8.40	8.51	9.23

Source: Company data, RHB



Results At a Glance

Figure 1: LHIB's results review

FYE Dec	3Q24	2Q25	3Q25	QoQ	YoY	9M24	9M25	YoY	Comments
(MYRm)				(%)	(%)			(%)	
Revenue	2,228.3	2,133.5	2,209.7	3.6	(0.8)	6,994.3	6,554.1	(6.3)	9M25 declined due to lower ASPs to pass on lower
EDITO A	200.0	057.0	207.0	400	(0.0)	047.4	005.0	(0.5)	feed costs and unfavorable FX translation
EBITDA	309.3	257.3	306.9	19.3	(8.0)	846.4	825.3	(2.5)	
EBITDA margin (%)	13.9	12.1	13.9	1.8	0.0	12.1	12.6	0.5	
EBIT	232.8	180.8	229.5	26.9	(1.4)	612.6	595.0	(2.9)	
EBIT Margin (%)	10.4	8.5	10.4	1.9	(0.1)	8.8	9.1	0.3	
Finance costs	(31.0)	(25.0)	(23.8)			(101.4)	(75.1)		
EI	(10.0)	0.0	(11.5)			(10.0)	(11.5)		Reversal of impairments on PPE booked in 3Q25
Profit before tax	201.9	156.0	205.8	31.9	1.9	511.3	520.1	1.7	
PBT Margin (%)	9.1	7.3	9.3	2.0	0.3	7.3	7.9	0.6	
Tax expense	(16.2)	(37.3)	(42.3)	13.3	162.0	(86.5)	(97.4)	12.5	
Effective tax rate (%)	(8.0)	(23.9)	(20.6)	3.4	(12.6)	(16.9)	(18.7)	(1.8)	
Minority interests	50.7	28.3	34.3			136.7	101.5		
PATAMI	135.0	90.3	129.1	43.0	(4.4)	288.1	321.2	11.5	
Core PATAMI	125.0	90.3	117.7	30.3	(5.9)	278.1	309.8	11.4	At 80%-82% of the forecasts
Net Margin (%)	5.6	4.2	5.3	1.1	(0.3)	4.0	4.7	0.8	

Source: Company data, RHB

Figure 2: LHIB's geographical breakdown

FYE Dec	3Q24	2Q25	3Q25	QoQ	YoY	9M24	9M25	YoY	Comments
(MYRm)				(%)	(%)			(%)	
Malaysia	567.2	588.2	584.8	(0.6)	3.1	1,723.1	1,734.7	0.7	
Singapore	209.0	198.8	210.9	6.1	0.9	623.4	615.1	(1.3)	
Vietnam	451.2	390.0	390.7	0.2	(13.4)	1,390.1	1,182.0	(15.0)	
Indonesia	816.7	762.4	804.0	5.5	(1.6)	2,734.3	2,423.1	(11.4)	
Philippines	181.3	190.8	216.0	13.2	19.2	514.9	589.0	14.4	
Group revenue	2,225.5	2,130.1	2,206.5	3.6	(0.9)	6,985.7	6,544.1	(6.3)	
Malaysia	141.8	150.5	133.5	(11.3)	(5.8)	347.7	408.1	17.4	Steady growth underpinned by favourable market conditions
Singapore	13.5	14.8	20.4	38.5	51.2	48.9	47.6	(2.7)	Conditions
Vietnam	63.8	45.8	54.9	19.8	(14.0)	137.6	148.3	7.8	
Indonesia	46.2	12.1	61.9	411.0	33.9	220.7	119.1	(46.0)	Sharp QoQ recovery thanks to recovery in ASPs
Philippines	43.9	34.2	36.1	5.7	(17.7)	91.4	102.2	11.8	
Group EBITDA	309.3	257.3	306.9	19.3	(8.0)	846.3	825.3	(2.5)	
Malaysia	25.0	25.6	22.8	(2.8)	(2.2)	20.2	23.5	3.3	
Singapore	6.5	7.4	9.7	2.3	3.2	7.8	7.7	(0.1)	
Vietnam	14.1	11.7	14.0	2.3	(0.1)	9.9	12.5	2.6	
Indonesia	5.7	1.6	7.7	6.1	2.0	8.1	4.9	(3.2)	
Philippines	24.2	17.9	16.7	(1.2)	(7.5)	17.8	17.4	(0.4)	
G.EBITDA margin (%)	13.9	12.1	13.9	1.8	0.0	12.1	12.6	0.5	

Source: Company data, RHB

Recommendation Chart



Source: RHB, Bloomberg

Date	Recommendation	Target Price	Price
2025-05-30	Buy	0.98	0.63
2025-02-26	Buy	0.98	0.63
2024-11-27	Buy	0.90	0.64
2024-08-27	Buy	0.84	0.59
2024-05-30	Buy	0.82	0.55
2024-02-28	Neutral	0.78	0.61
2023-11-29	Neutral	0.74	0.68
2023-10-22	Buy	0.72	0.61
2023-08-29	Buy	0.63	0.53
2023-06-01	Buy	0.63	0.51
2023-02-28	Buy	0.63	0.50
2022-11-29	Buy	0.61	0.49
2022-05-25	Buy	0.61	0.50
2022-02-23	Buy	0.83	0.56
2021-11-24	Buy	0.83	0.56

Source: RHB, Bloomberg

RHB Guide to Investment Ratings

Buy: Share price may exceed 10% over the next 12 months

Trading Buy: Share price may exceed 15% over the next 3 months, however longer-

term outlook remains uncertain

Neutral: Share price may fall within the range of +/- 10% over the next

12 months

 Take Profit:
 Target price has been attained. Look to accumulate at lower levels

 Sell:
 Share price may fall by more than 10% over the next 12 months

Not Rated: Stock is not within regular research coverage

Investment Research Disclaimers

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report may contain comments, estimates, projections, forecasts and expressions of opinion relating to macroeconomic research published by RHB economists of which should not be considered as investment ratings/advice and/or a recommendation by such economists on any securities discussed in this report.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies

RESTRICTIONS ON DISTRIBUTION

Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Berhad ("RHBIB"). The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHBIB has no obligation to update its opinion or the information in this report.

Indonesia

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any



Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.

Singapore

This report is issued and distributed in Singapore by RHB Bank Berhad (through its Singapore branch) which is an exempt capital markets services entity and an exempt financial adviser regulated by the Monetary Authority of Singapore. RHB Bank Berhad (through its Singapore branch) may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Bank Berhad (through its Singapore branch) accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Bank Berhad (through its Singapore branch) in respect of any matter arising from or in connection with the report.

United States

This report was prepared by RHB is meant for distribution solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act") via a registered U.S. broker-dealer as appointed by RHB from time to time. Accordingly, any access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors (via a registered U.S broker-dealer), nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and currently has not appointed a U.S. broker-dealer. Additionally, RHB does not offer brokerage services to U.S. persons. Any order for the purchase or sale of all securities discussed herein must be placed with and through a registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. For avoidance of doubt, RHB reiterates that it has not appointed any U.S. broker-dealer during the issuance of this report. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of any registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

DISCLOSURE OF CONFLICTS OF INTEREST

RHB Investment Bank Berhad, its subsidiaries (including its regional offices) and associated companies, ("RHBIB Group") form a diversified financial group, undertaking various investment banking activities which include, amongst others, underwriting, securities trading, market making and corporate finance advisory.

As a result of the same, in the ordinary course of its business, any member of the RHBIB Group, may, from time to time, have business relationships with, hold any positions in the securities and/or capital market products (including but not limited to shares, warrants, and/or derivatives), trade or otherwise effect transactions for its own account or the account of its customers or perform and/or solicit investment, advisory or other services from any of the subject company(ies) covered in this research report.

While the RHBIB Group will ensure that there are sufficient information barriers and internal controls in place where necessary, to prevent/manage any conflicts of interest to ensure the independence of this report, investors should also be aware that such conflict of interest may exist in view of the investment banking activities undertaken by the RHBIB Group as mentioned above and should exercise their own judgement before making any investment decisions.

In Singapore, investment research activities are conducted under RHB Bank Berhad (through its Singapore branch), and the disclaimers above similarly apply.

Malaysia

Save as disclosed in the following link RHB Research Conflict Disclosures Nov 2025 and to the best of our knowledge, RHBIB hereby declares that:

- RHBIB does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
- RHBIB is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
- None of RHBIB's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report
 *For the avoidance of doubt, the confirmation is only limited to the staff of research
- RHBIB did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.

RHBIB did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Indonesia

Save as disclosed in the following link RHB Research Conflict Disclosures Nov 2025 and to the best of our knowledge, PT RHB Sekuritas Indonesia hereby declares that:

- PT RHB Sekuritas Indonesia and its investment analysts, does not have any interest in the securities of the subject company(ies) covered in this report.
 - For the avoidance of doubt, interest in securities include the following:
 - Holding directly or indirectly, individually or jointly own/hold securities or entitled for dividends, interest or proceeds from the sale or exercise of the subject company's securities covered in this report*;
 - b) Being bound by an agreement to purchase securities or has the right to transfer the securities or has the right to pre subscribe the securities*.
 - c) Being bound or required to buy the remaining securities that are not subscribed/placed out pursuant to an Initial Public Offering*.
 - d) Managing or jointly with other parties managing such parties as referred to in (a), (b) or (c) above.
- 2. PT RHB Sekuritas Indonesia is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
- 3. None of PT RHB Sekuritas Indonesia's staff** or associated person serve as a director or board member* of the subject company(ies) covered in this report.
- 4. PT RHB Sekuritas Indonesia did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- 5. PT RHB Sekuritas Indonesia** did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report:

Notes:

*The overall disclosure is limited to information pertaining to PT RHB Sekuritas Indonesia only.

**The disclosure is limited to Research staff of PT RHB Sekuritas Indonesia only.

Singanore

Save as disclosed in the following link <u>RHB Research Conflict Disclosures Nov 2025</u> and to the best of our knowledge, the Singapore Research department of RHB Bank Berhad (through its Singapore branch) hereby declares that:

- RHB Bank Berhad, its subsidiaries and/or associated companies do not make a market in any issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies and its analysts
 do not have a financial interest (including a shareholding of 1% or more) in the
 issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad's Singapore research staff or connected persons do not serve
 on the board or trustee positions of the issuer covered by the Singapore research
 analysts in this report.
- 4. RHB Bank Berhad, its subsidiaries and/or its associated companies do not have and have not within the last 12 months had any corporate finance advisory relationship with the issuer covered by the Singapore research analysts in this report or any other relationship that may create a potential conflict of interest.
- RHB Bank Berhad, or person associated or connected to it do not have any interest in the acquisition or disposal of, the securities, specified securities based derivatives contracts or units in a collective investment scheme covered by the Singapore research analysts in this report.
- RHB Bank Berhad's Singapore research analysts do not receive any compensation
 or benefit in connection with the production of this research report or
 recommendation on the issuer covered by the Singapore research analysts.

Analyst Certification

The analyst(s) who prepared this report, and their associates hereby, certify that: (1) they do not have any financial interest in the securities or other capital market products of the subject companies mentioned in this report, except for:

Analys	st	Company
-		-

(2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.





KUALA LUMPUR

RHB Investment Bank Bhd

Level 3A, Tower One, RHB Centre Jalan Tun Razak Kuala Lumpur 50400 Malaysia

Tel:+603 2302 8100 Fax:+603 2302 8134

SINGAPORE

RHB Bank Berhad (Singapore branch)

90 Cecil Street #04-00 RHB Bank Building Singapore 069531 Fax: +65 6509 0470

JAKARTA

PT RHB Sekuritas Indonesia

Revenue Tower, 11th Floor, District 8 - SCBD Jl. Jendral Sudirman Kav 52-53 Jakarta 12190 Indonesia

Tel: +6221 5093 9888 Fax: +6221 5093 9777

